Home › Funds › Affinity Asset Advisors, LLC › JBIO
Affinity Asset Advisors, LLC position in JBIO
JADE BIOSCIENCES INC · Health Care
Affinity Asset Advisors, LLC reported holding 760,350 shares of JBIO (JADE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$10.7M, representing 0.50% of its reported portfolio and ranking #46 among its reported holdings. Affinity Asset Advisors, LLC has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's JBIO position evolved
Affinity Asset Advisors, LLC first disclosed a stake in JBIO in Q2 2025 at 65,317 shares (US$653K). The position peaked in Q2 2026 at 840,350 shares, worth US$18.7M. Across 6 filings, Affinity Asset Advisors, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 760,350 shares valued at US$10.7M — a reduction of -80,000 shares quarter over quarter.. Notable position changes include a 995% increase in Q4 2025 (shares fell 9% over the following quarter), a 31% increase in Q2 2026 (shares fell 37% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 65.32K | $652.52K | New |
| Q3 2025 | 65.32K | $563.69K | Hold |
| Q4 2025 | 714.96K | $11.03M | Add |
| Q1 2026 | 639.96K | $8.99M | Reduce |
| Q2 2026 | 840.35K | $18.67M | Add |
| Q3 2026 | 760.35K | $10.68M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About JBIO and 13F data
JBIO (JADE BIOSCIENCES INC) is a Health Care company. 94 other funds we track also report a position in JBIO — the largest reported positions include Fairmount Funds Management LLC (US$101.2M), RA CAPITAL MANAGEMENT, L.P. (US$81.6M), Venrock Adviser, LLC (US$71.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding JBIO
- Fairmount Funds Management LLC 4.55M sh · $101.18M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 3.67M sh · $81.57M · Q2 2026
- Venrock Adviser, LLC 3.22M sh · $71.56M · Q2 2026
- Bellevue Group AG 3.06M sh · $67.95M · Q2 2026
- Paradigm Biocapital Advisors LP 2.86M sh · $63.49M · Q2 2026
- Avidity Partners Management LP 1.70M sh · $37.79M · Q2 2026
- Soleus Capital Management, L.P. 1.55M sh · $34.46M · Q2 2026
- BAKER BROS. ADVISORS LP 1.23M sh · $27.34M · Q2 2026
- Remedium Capital Partners, LLC 1.81M sh · $25.40M · Q3 2026
- Logos Global Management LP 1.12M sh · $25.00M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 986.76K sh · $21.93M · Q2 2026
- Foresite Capital Management VI LLC 886.67K sh · $19.70M · Q2 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held JBIO?
Affinity Asset Advisors, LLC has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Affinity Asset Advisors, LLC's current position in JBIO?
As of Q3 2026, Affinity Asset Advisors, LLC holds 760.35K shares of JBIO (JADE BIOSCIENCES INC), valued at $10.68M, representing 0.50% of its reported portfolio and ranking #46.
Has Affinity Asset Advisors, LLC been buying or selling JBIO?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC reduced its position in JBIO. The position peaked in Q2 2026 at 840.35K shares.
Which other funds hold JBIO?
Other major institutional holders of JBIO include Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Venrock Adviser, LLC, among 94 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.